Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.57B |
| 2 |
Tesla
TSLA
|
+$1.06B |
| 3 |
Amazon
AMZN
|
+$597M |
| 4 |
Qualcomm
QCOM
|
+$374M |
| 5 |
AbbVie
ABBV
|
+$373M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.54B |
| 2 |
Johnson & Johnson
JNJ
|
+$561M |
| 3 |
UnitedHealth
UNH
|
+$353M |
| 4 |
Meta Platforms (Facebook)
META
|
+$345M |
| 5 |
Starbucks
SBUX
|
+$340M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 21.63% |
| 2 | Technology | 13.19% |
| 3 | Consumer Discretionary | 10.53% |
| 4 | Financials | 8.74% |
| 5 | Communication Services | 7.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2076
Ross Stores
ROST
$78.7B
| $3.38M | ﹤0.01% |
29,000
-671,228
| -96% | -$75.5M |
|
|
EGIO
2077
DELISTED
Edgio, Inc. Common Stock
EGIO
| $3.38M | ﹤0.01% |
20,688
-27,504
| -57% | -$4.35M |
|
2078
UTStarcom
UTSI
$23.5M
| $3.37M | ﹤0.01% |
285,757
-2,761
| -1% | -$32.8K |
|
2079
AZZ Inc
AZZ
$4.55B
| $3.35M | ﹤0.01% |
72,900
-195,063
| -73% | -$7.97M |
|
|
TUES
2080
DELISTED
Tuesday Morning Corp
TUES
| $3.35M | ﹤0.01% |
1,809,951
+274,004
| +18% | +$436K |
|
2081
AstroNova
ALOT
$227M
| $3.34M | ﹤0.01% |
243,450
-7,400
| -3% | -$113K |
|
|
BLCM
2082
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
| $3.33M | ﹤0.01% |
258,384
-1,722
| -0.7% | -$15.9K |
|
2083
Children's Place
PLCE
$54.3M
| $3.3M | ﹤0.01% |
+52,760
| New | +$3.85M |
|
2084
Tencent Music
TME
$14.5B
| $3.3M | ﹤0.01% |
+280,900
| New | +$3.61M |
|
|
UBFO
2085
DELISTED
United Security Bancshares
UBFO
| $3.29M | ﹤0.01% |
306,940
+38,228
| +14% | +$397K |
|
2086
Kingstone Companies
KINS
$285M
| $3.29M | ﹤0.01% |
424,700
+40,800
| +11% | +$324K |
|
2087
Cass Information Systems
CASS
$748M
| $3.29M | ﹤0.01% |
56,972
-23,517
| -29% | -$1.32M |
|
2088
CSP Inc
CSPI
$81.1M
| $3.28M | ﹤0.01% |
502,500
-7,000
| -1% | -$45.5K |
|
2089
AmeriServ Financial
ASRV
$85M
| $3.26M | ﹤0.01% |
776,408
+11,964
| +2% | +$49.9K |
|
2090
Alphatec Holdings
ATEC
$1.51B
| $3.25M | ﹤0.01% |
458,787
+48,800
| +12% | +$313K |
|
2091
Spero Therapeutics
SPRO
$71.2M
| $3.25M | ﹤0.01% |
338,203
+85,400
| +34% | +$921K |
|
|
ADXS
2092
DELISTED
Advaxis Inc
ADXS
| $3.24M | ﹤0.01% |
3,780,083
+1,800,297
| +91% | +$821K |
|
2093
ABM Industries
ABM
$2.82B
| $3.23M | ﹤0.01% |
85,700
-500
| -0.6% | -$18.7K |
|
2094
InfuSystem Holdings
INFU
$244M
| $3.22M | ﹤0.01% |
377,503
+43,550
| +13% | +$321K |
|
2095
Miller Industries
MLR
$645M
| $3.21M | ﹤0.01% |
86,600
-3,100
| -3% | -$109K |
|
2096
First United
FUNC
$293M
| $3.21M | ﹤0.01% |
133,399
+61,397
| +85% | +$1.45M |
|
|
CRHM
2097
DELISTED
CRH Medical Corporation
CRHM
| $3.2M | ﹤0.01% |
922,423
+236,823
| +35% | +$748K |
|
2098
Eagle Bancorp
EGBN
$878M
| $3.19M | ﹤0.01% |
65,580
+20,500
| +45% | +$928K |
|
2099
Global Water Resources
GWRS
$247M
| $3.18M | ﹤0.01% |
241,692
+14,567
| +6% | +$183K |
|
2100
Mastercard
MA
$499B
| $3.17M | ﹤0.01% |
+10,600
| New | +$2.99M |
|
Similar funds
Jim Simons's Q4 2019 Portfolio in Review
As of Q4 2019, Jim Simons held 3,913 positions worth $130B, up 10% from $118B the previous quarter. Its ten largest holdings account for 13% of the portfolio.
Jim Simons's Q4 2019 filing shows 518 new, 1,836 increased, 1,085 reduced and 443 closed positions. Its largest new stake was Amazon: 6,745,100 shares worth $623M. The largest sale was Celgene Corp, an estimated $1.54B.
By sector, the portfolio is most concentrated in Healthcare at 22% of assets, up from 19% a quarter earlier, followed by Technology and Consumer Discretionary.
- Jim Simons's largest Q4 2019 buy was Amazon: 6,745,100 shares worth $623M.
- Jim Simons added most to Bristol-Myers Squibb in Q4 2019, an estimated $1.57B increase.
- Jim Simons's biggest Q4 2019 reduction was Johnson & Johnson, cutting an estimated $561M.
- Jim Simons fully exited Celgene Corp in Q4 2019, selling an estimated $1.54B.
- Jim Simons's ten largest holdings make up 13% of its $130B portfolio in Q4 2019.
- Jim Simons opened 518 new positions and closed 443 in Q4 2019.
- Jim Simons's portfolio value rose 10% quarter-over-quarter to $130B.
Based on Renaissance Technologies's 13F filing for Q4 2019, filed 13 Feb 2020.